rebalanc china exposur execut keep ep growth
spite fx tariff macro outlook
relief china concern mtd outlook close cap period
uncertainti moder china macro histor pressur
result china growth quarter modestli stronger
compound basi expect stronger yr/yr growth easier comp
key stronger result upsid expect
substanti rebalanc custom mix china last year
fulli quantifi higher concentr pharma chemic
shift away materi mute china cyclic spite
industri mix remain elev credit avail china remain posit
unlik cycl see sign breakdown demand/ord trend
first look guidanc manag remain confid continu
strong end-market demand reiter caution global economi
potenti long term impact china trade situat revenu
expect remain organ emb fx tariff headwind
spite tariff fx ep guidanc rais
importantli manag provid initi guidanc org revenue growth
adj ep impli upsid consensu spite
fx tariff greater drag ep forecast assum
acceler industri full year impact tariff expect
includ impact second wave vs prior guidanc
expect meaning off-set headwind
observ quarter quarter lab growth top
tough comp retail beat growth driven project activ
us industri quarter core industri grew top
comp product inspect slightli quarter due
strong key account driven tough comp capital-expenditure manag packag
food compani pre-invest chang us manufactur
footprint sale growth china stood broad-bas
top comp gm due price tariff headwind
advers mix initi cost associ us facil consolid new
nomin model chang pt remain make nomin chang
mode lower revenu estim ebit margin
assumpt increas overal ep increas
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt remain base yield
roll estim
deriv base case scenario
bull case ep
bull case ep
robust cyclic recoveri along momentum lab growth food
retail lead sustain hsd top-line growth ebit margin expand
driven effici initi stronger price power multipl
expand ep ep growth
base ep
base ep
price target deriv target fcfi
premium tool peer in-lin histor averag outlook
incorpor organ growth driven normal industri
environ msd-hsd lab growth lsd food retail growth margin
expand yy price cost program multipl contract
ep in-lin three-year averag ep growth
bear ep
bear ep
china industri slow lab growth stall tougher comp food retail
declin project time lead lsd top-line growth oper margin
expand given increas spend field turbo less price power
expect multipl contract in-lin ten-year averag
decomposit valuat near-
term long-term growth compon
use price
analysi suggest view sustain
strong sale margin trend appear
factor current stock price limit
excess return versu peer coverag
visibl consist margin
expans growth support high
multipl rel multipl vs tool
 higher long-term
multipl appropri given above-p
comparison measur
confound low mix intang
exposur china industri
highest coverag introduc greater
element cyclic uncertainti
spinnak enabl target sale
market lead sustain market
increas focu servic attach rate
growth spur revenu profit gain
strong manag track record
risk achiev price
margin expans weigh sale
recoveri china slower expect
exhibit pmi remain across geographi us
acceler straight month europ deceler
peak march
morgan stanley research ism
note morgan stanley short cycl growth index geograph weight averag short cycl
industri growth indic index track individu industri data point span region
car sale machin tool demand bear demand machineri sale
exhibit chang forecast
guidanc
biotix acq
guidanc
organ
biotix
sale
sale
sale
sale
sale
sale
million except ep
valuat risk
exhibit capit effici support higher multipl
thomson reuter morgan stanley research
bloomberg thomson reuter morgan stanley research
thomson reuter morgan stanley research
exhibit rel price-to-earnings vs
thomson reuter morgan stanley research
price target impli yield
estim outlook incorpor organ growth organ
ebit margin expans impli multipl ep
upsid risk price target includ sustain macro recoveri drive hsd industri
growth continu msd-hsd lab growth better expect margin expans
robust cost program downsid risk includ slowdown cyclic indic
slower expect margin expans weak lab/food retail growth
earn tax
provis tax
revenu product area
sale
sale
sale
total revenu product area
